Studies investigating event-related potential (ERP) evoked in a Cue-Go/NoGo paradigm have shown lower frontal N1, N2 and central P3 in children with attention-deficit/hyperactivity disorder (ADHD) compared to typically developing children (TDC). However, the electroencephalographic (EEG) dynamics underlying these ERPs remain largely unexplored in ADHD.
This article was published in the following journal.
Name: Brain sciences
ISSN: 2076-3425
Pages:
Current diagnostic systems conceptualise attention deficit hyperactivity disorder (ADHD), oppositional defiant/conduct disorder (ODD/CD) and autism spectrum disorder (ASD) as separate diagnoses. Howev...
EEG phase states at stimulus onset in a variable-ISI Go/NoGo task: Effects on ERP components.
Previous EEG-ERP dynamics studies found non-random "preferred" EEG phases at stimulus onset in a fixed interstimulus interval (ISI) equiprobable auditory Go/NoGo paradigm, with substantial effects on ...
It has been unclear whether an associations of child ADHD with socio-economic disadvantage (SES) could be accounted for by (a) parental ADHD explaining both low SES and child ADHD, and/or (b) the join...
The current body of evidence suggests that an aerobic exercise session has a beneficial effect on inhibitory control, whereas the impact of coordinative exercise on this executive function has not yet...
Thyroid Hormone Status in Overweight Children with Attention Deficit/Hyperactivity Disorder.
There is an ongoing discussion whether thyroid hormones are involved in the development and course of attention deficit/hyperactivity disorder (ADHD). Since obesity is associated with both higher thyr...
Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD
This study evaluates the ability to support diagnosis and monitor of the dynamics in ADD/ADHD subjects with an easy to use EEG Device.
The researchers plan to explore the validity of the category of ADHD NOS by identifying the risk for ADHD in the children of ADHD NOS adult probands and identifying common correlates of AD...
Impaired WM is a central deficit in ADHD. A computerized training program, Cogmed, has been shown to increase WM capacity in children with ADHD. It is not known whether the training improv...
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate...
Central Executive Training (CET) for ADHD
The goal of the current project is to assess the efficacy of Central Executive Training (CET) for youth with ADHD. CET is a new, computerized training intervention that targets specific co...
Nogo Proteins
Myelin proteins that are expressed as three isoforms: Nogo-A, Nogo-B, and Nogo-C. These share a C-terminal reticulon homology domain (RHD), consisting of two hydrophobic membrane domains flanking a 66 amino acid (Nogo-66) hydrophilic region. A long transmembrane region allows conformations that either span the entire membrane or fold into a hairpin conformation. Nogo inhibits NEURITE outgrowth and modulates wiring and the restriction of SYNAPTIC PLASTICITY in the adult central nervous system. It also regulates neurite fasciculation, branching, and extension in the developing nervous system.
Nogo Receptors
GPI-linked proteins consisting of eight elongated leucine-rich repeats at their N-temini that are connected to the GPI by a "stalk" region rich in prolines, serines and threonines. They bind to NOGO PROTEIN; however, some Nogo receptors also bind MYELIN ASSOCIATED GLYCOPROTEIN and other cell surface glycoproteins. Interactions between nogo receptors and their ligands modulate nerve growth and NEURONAL PLASTICITY.
Nogo Receptor 2
A Nogo receptor that binds to MYELIN-ASSOCIATED GLYCOPROTEIN. It localizes to the GROWTH CONES of neurons in the THALAMUS; CORTEX: AMYGDALA; OLFACTORY BULBS; and HYPOTHALAMUS.
Time And Motion Studies
The observation and analysis of movements in a task with an emphasis on the amount of time required to perform the task.
Nogo Receptor 1
A high affinity receptor for myelin-associated inhibitors (MAIs) that include NOGO-A PROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; and MYELIN-ASSOCIATED GLYCOPROTEIN. It is expressed primarily by neurons in the brain and OLFACTORY BULBS. During embryonic development, it is expressed in the PERIPHERAL NERVOUS SYSTEM. It localizes to GROWTH CONES and may inhibit neurite outgrowth following SPINAL INJURY.